Skip to main content
Premium Trial:

Request an Annual Quote

Novartis Using CST s Phosphoscan in Pilot Study

NEW YORK, Aug. 3 (GenomeWeb News) - Novartis has been using Cell Signaling Technology's PhosphoScan in a pilot study to identify phosphorylation sites and prospective biomarkers of protein kinase targets, CST said yesterday.

 

Novartis researchers can now use CST's PhosphoScan -- a tool that pairs immunoaffinity purification protocol and mass spectrometry technology -- to develop cellular kinase phosphor-profiles that CST said may be useful in creating biomarker assays for target validation.